Emerging evidence for skeletal muscle as a target of BPA exposure Authors: Muneebah Vaid, Hilda Dahbur, Hadi Dahbour, Isabel Martinez-Pena y Valenzuela Published: 2026 ABSTRACT AbstractEndocrine disruptors are exogenous chemicals that interfere with hormonal signaling, and among them, bisphenol-A (BPA) is one of the most widely used and globally prevalent. Human exposure to BPA occurs through multiple routes, and measurable levels are detected in the majority of biological samples worldwide. At the molecular level, BPA interacts with several nuclear and membrane receptors, conferring estrogenic and anti-androgenic properties that disrupt endocrine, metabolic, and cardiovascular systems. Although the biological effects of BPA have been extensively studied in reproductive, neural, hepatic, and adipose tissues, its impact on skeletal muscle has been comparatively understudied, despite the central role of this tissue in glucose homeostasis and energy metabolism. In addition, direct human evidence specifically linking BPA exposure to skeletal muscle structure or function remains limited. This review summarizes current evidence regarding the effects of BPA on skeletal muscle structure and function. Experimental studies indicate that BPA disrupts insulin signaling in skeletal muscle by impairing insulin receptor-dependent pathways, reducing Akt phosphorylation and GLUT4 translocation, and promoting inflammatory responses, ultimately leading to insulin resistance and glucose intolerance. Developmental exposure to BPA further alters muscle fiber composition, gene expression, calcium signaling, and excitation-contraction coupling, with persistent effects on muscle phenotype and function. Collectively, the findings reviewed here identify skeletal muscle as a critical, yet underrecognized, target of BPA toxicity and underscore the need for future studies addressing chronic low-dose exposure and long-term outcomes, particularly in human populations.Keywords: Endocrine disruptors, Bisphenol-A, Skeletal muscle, Insulin signaling, Inflammation Endocrine disruptors and bisphenol A: sources, exposure, and health relevance Endocrine disruptors are chemicals that interfere with normal endocrine function by mimicking or inhibiting endogenous hormones. These chemicals can be found in a variety of sources, including plastic bottles, metal food cans, cosmetics, pesticides, flame retardants, as well as food and water sources [1, 2]. Among these, bisphenol-A (BPA) is one of the most widely used endocrine disruptors, resulting in pervasive human exposure [3, 4]. BPA is a diphenylmethane derivative containing two hydroxyphenyl groups, which confer high solubility in organic solvents. This property has been exploited extensively industrially for the production of synthetic polymers and epoxy resins [5, 6]. Environmental contamination occurs when BPA leaches from pipes or industrial products into soil and water. Humans are exposed to BPA through multiple routes, including maternal-fetal transfer, dermal and ocular contact, inhalation, and ingestion. The USA Environmental Protection Agency (EPA) has established a safety threshold for human BPA exposure at 50 µg/kg of body weight. BPA has been detected in human serum, amniotic fluid, placental tissue, and umbilical cord blood [7–11], and over 90% of urine samples from adults in the United States, Europe, and Asia contain measurable BPA, highlighting its global prevalence [3]. Higher urinary BPA levels have been associated with an increased risk of diabetes, altered liver enzyme profiles, and cardiovascular disease [7, 12–14]. BPA has a relatively short half-life and is rapidly metabolized in the liver and gut [15], primarily forming BPA-glucuronide [16], a metabolite that is excreted in urine. Unconjugated BPA can also undergo sulfation to form BPA-sulfate [17]. While these conjugates were once considered inactive, emerging evidence indicates that both BPA-glucuronide and BPA-sulfate can retain measurable bioactivity, suggesting that they may contribute to BPA’s overall biological effects [18, 19]. The kinetics of BPA vary by route of exposure: following oral dosing, conjugation is rapid, and elimination of metabolites into urine largely occurs within 24 h in humans [20], whereas dermal exposure results in slower systemic clearance and a longer half-life [21]. Conjugated forms of BPA may persist longer in the body, as suggested by pharmacokinetic studies [22]. While glucuronidation represents the predominant metabolic pathway, minor quantities of other metabolites, including oxidative derivatives, have also been described [23, 24]. Although BPA is generally considered to have low persistence in the human body following exposure [20], some studies have detected BPA in adipose tissue, suggesting partial storage. BPA has been measured in human adipose tissue in a limited number of studies [25, 26], and while the long-term metabolic and functional consequences remain somewhat speculative, tissue accumulation may contribute to biologically relevant endocrine and metabolic effects. Biomonitoring studies indicate that urinary BPA levels do not consistently decline with fasting time, suggesting continuous exposure, slower effective clearance, or release from endogenous stores [27]. The potential long-term metabolic and functional consequences of adipose sequestration in humans remain unknown. A critical issue in interpreting BPA toxicity is the distinction between environmentally relevant human exposures and the supraphysiologic doses frequently used in experimental studies. Biomonitoring studies indicate that typical human exposure results in urinary BPA concentrations in the range of 1–10 ng/mL, with circulating unconjugated BPA generally detected at sub-nanomolar to low-nanomolar concentrations [3, 7]. In contrast, many in vitro studies, particularly those assessing cytotoxicity, utilize BPA concentrations in the micromolar range (≥ 1–100 µM) [28, 29]. For example, exposing primary human granulosa cells to concentrations as high as 20,000 ng/mL demonstrates significant alterations in extracellular vesicle-associated miRNA expression, but these concentrations are clearly supraphysiological [30]. In vivo animal studies often employ doses significantly higher than the 50 µg/kg/day safety threshold established by the USA Environmental Protection Agency (EPA) [31–33]. Because BPA exhibits non-monotonic dose-response relationships [3, 4], biologically significant effects can occur at low doses that are often missed in high-dose exposure. Therefore, it is crucial to consider dose relevance when interpreting toxicity, and it highlights the necessity of focusing on chronic, low-dose models to understand the true risk BPA poses to human metabolic health. Molecular targets and endocrine-disrupting mechanisms of BPA At the molecular level, BPA acts by interacting with multiple nuclear and membrane receptors. BPA’s well-characterized endocrine-disrupting mechanisms involve binding to key hormone receptors, including estrogen receptors (ERα and ERβ) [34, 35], estrogen-related receptor γ (ERRγ) [36, 37], the pregnane X receptor (PXR) [38, 39], and the G-protein-coupled estrogen receptor (GPR30/GPER) [40, 41]. It also antagonizes the androgen receptor (AR) [42] and interferes with progesterone receptor (PR) [39, 43] and thyroid hormone receptors (TRα and TRβ) signaling [44, 45]. Through these diverse receptor-mediated interactions, BPA disrupts multiple hormonal signaling pathways and downstream transcriptional programs. As a consequence, BPA exhibits both estrogenic and anti-androgenic effects. In addition, BPA disrupts immune [46, 47], neuroendocrine [48–50], and reproductive systems [48, 51, 52], and has been linked to adverse impacts on cardiac physiology [53–55], and skeletal muscle function [56, 57]. Despite extensive research on the endocrine-disrupting properties of BPA, most studies have focused on its effects in reproductive, neural [48–52, 58], hepatic [59, 60], and adipose tissues [61, 62], leaving its influence on skeletal and, to a lesser extent, cardiac muscle comparatively understudied. This gap is notable because striated muscles are major regulators of whole-body energy metabolism and contain multiple membrane and nuclear receptors [63, 64] that can be targeted by BPA. Understanding how BPA disrupts muscle-specific endocrine and metabolic signaling is, therefore, essential, as such disturbances can contribute to broader physiological outcomes, including insulin resistance, cardiac dysfunction, and muscle wasting. Metabolic programming and insulin signaling disruption in skeletal muscle In skeletal muscle, insulin promotes glucose uptake by activating its receptor and triggering downstream signaling through IRS-1, PI3K, and Akt. This cascade drives the translocation of the glucose transporter GLUT4 to the plasma membrane, facilitating glucose entry into the cell. Proper functioning of this pathway is essential for glucose homeostasis and is sensitive to modulation by pro-inflammatory cytokines, such as TNF-α, which can impair IRS-1 and PI3K/Akt signaling and reduce insulin-stimulated glucose uptake [65–67]. Skeletal muscle plays a fundamental role in locomotion, posture support, breathing, and glucose metabolism [68]. Given that nearly 80% of glucose uptake occurs in skeletal muscle, disruption of this tissue has significant metabolic consequences. BPA acts as a xenoestrogen and disrupts insulin signaling through multiple mechanisms in insulin-sensitive tissues, including the liver [69, 70], adipose tissue [71, 72], and skeletal muscle [70, 72, 73]. Among these, skeletal muscle represents a major target of BPA-induced metabolic dysfunction. In rodents, BPA reduces insulin receptor expression and phosphorylation, inhibits downstream PI3K-Akt signaling, and decreases GLUT4 translocation, collectively diminishing insulin-stimulated glucose uptake [74, 75]. Specifically, in skeletal muscle of male rats, BPA exposure has been shown to impair Akt phosphorylation and GLUT4 translocation [74], while some studies report no significant changes in insulin receptor expression or its basic function [73], ultimately resulting in reduced glucose oxidation and glycogen content. A complementary study showed the effects of long-term oral BPA exposure in male rats [73]. Rats receiving BPA orally (20 and 200 mg/kg body weight per day for 28 days) developed glucose intolerance and insulin resistance, along with reduced adiponectin levels, suggesting that BPA disrupts metabolic and hormonal regulation associated with insulin sensitivity. Similarly, in growing male mice, long-term oral BPA exposure (50 µg/kg body weight per day for 12 weeks) alongside a high-fat diet induced glucose tolerance and insulin resistance, as reflected by a higher area under the curve during glucose tolerance testing, and reduced Akt phosphorylation in skeletal muscle [76]. BPA also stimulates insulin secretion from pancreatic β-cells via estrogen-receptor-mediated mechanisms, promoting hyperinsulinemia and contributing to insulin resistance [77, 78]. Early-life exposure at human-relevant doses (0.5 µg BPA/kg body weight/day) suppresses Irs1 promoter activity and reduces Irs1 expression in skeletal muscle, leading to insulin resistance in mice and in C2C12 myotubes through an estrogen receptor-α-mediated mechanism [75]. Similarly, BPA exposure in L6 myotubes increases basal glucose metabolism in an estrogen receptor-dependent manner while inducing insulin resistance [79]. Maternal BPA exposure during pregnancy and lactation in mice leads to insulin resistance and glucose intolerance later in life, with sex- and tissue-specific disruptions in insulin signaling in the offspring [80]. In rats, maternal BPA exposure also alters insulin signaling protein abundance in skeletal muscle of offspring, with reduced expression of key components across developmental stages in a sex- and tissue-specific manner [70]. Additionally, genome-wide transcriptomic analyses of mouse skeletal muscle show that BPA exposure induces the expression of genes associated with adaptive immune and inflammatory pathways [81], including upregulation of complement-related genes and Tnfα. Given the recognized health hazards of BPA, mechanistic insights have largely been derived from animal and in vitro models using controlled exposure paradigms that may not fully reflect typical human environmental exposure [82–84]. Consequently, the effects of chronic, low-dose BPA exposure (more representative of human exposure) on skeletal muscle remain insufficiently characterized. Developmental exposure to BPA may therefore program metabolic signaling pathways and alter the structural and functional properties of skeletal muscle. A major limitation in the literature is variability across experimental models, including species, sex, developmental stage, and exposure conditions, which complicates interpretation of BPA effects on skeletal muscle. Rodent studies have been instrumental in identifying mechanisms of insulin resistance but may not fully translate to humans due to species-specific metabolic and endocrine differences. Sex- and development-dependent effects are evident, with males often exhibiting impaired glucose tolerance and females showing relative protection, while early-life exposures produce long-lasting metabolic programming. In vitro systems, such as C2C12 or L6 myotubes, provide mechanistic insight but lack systemic physiological interactions. Together, these limitations highlight the need for integrative, sex- and age-specific approaches to improve translational relevance. Developmental and structural effects of BPA on skeletal muscle In addition to disrupting metabolic signaling, BPA can influence skeletal muscle development and structural organization. A study in sheep showed that gestational BPA exposure alters fetal skeletal muscle structure and gene expression [85]. Fetal muscles from BPA-exposed animals displayed larger myofibers in both sexes compared to controls. In female fetuses, MYH1 expression was increased, suggesting potential alterations in fiber-type composition, while no significant changes were observed in males. These results suggest that prenatal BPA exposure promotes a hypertrophic muscle phenotype, which may have implications for muscle function and metabolic responsiveness later in life, including potential susceptibility to fatigue in adulthood. Complementing these findings, studies in zebrafish have demonstrated that developmental BPA exposure can impair motor function and affect neuromuscular development [56]. Even at concentrations (1–15 µM) that do not produce overt teratogenic effects, BPA reduces spontaneous movement, decreases touch responsiveness, and slows swimming behavior. These behavioral alterations are associated with disruptions in axial musculature and, at higher concentrations, impaired motoneuron axonal growth. BPA-induced oxidative stress, DNA damage, and apoptosis have been proposed as underlying mechanisms contributing to these structural and functional effects, linking cellular level disturbances to motor impairments. Collectively, studies across species suggest that BPA can influence both skeletal muscle morphology and function, with potential long-term consequences for metabolic health and physical performance. Consistent with these findings, another study showed that BPA disrupts calcium signaling pathways in embryonic skeletal muscle myotubes, leading to impaired excitation-contraction coupling and developmental muscle dysfunction [57]. These studies provide insight into how BPA alters both structural and functional aspects of muscle, suggesting that even subtle developmental disruptions may have long-term consequences. Although most evidence comes from animal and in vitro studies, these molecular and structural changes have important implications for human skeletal muscle health, including insulin resistance, muscle weakness, and sarcopenia, which may ultimately impair physical function. Strengths, weaknesses, and methodological limitations of existing evidence Population-based data from the National Health and Nutrition Examination Survey (NHANES) further demonstrate that BPA exposure is widespread in the U.S., with detection in the majority of individuals and variability across demographic groups [3, 27, 86–89], and longitudinal analyses suggest modest declines in exposure over time, although BPA remains consistently detectable in the U.S. population [3, 90, 91]. BPA research in skeletal muscle consistently identifies conserved molecular targets such as Akt/GLUT4 signaling and Irs1 promoter activity across diverse models [73–75, 79]. However, many studies rely on animal models, often involving higher or non-environmental doses. Furthermore, while human epidemiological studies have linked elevated urinary BPA to systemic metabolic disorders such as diabetes, cardiovascular disease, non-alcoholic fatty liver disease, and kidney disease, direct evidence regarding muscle-specific outcomes remains limited [7, 12–14, 90−92]. Variability in species, sex, developmental stage, exposure routes, doses, and measured endpoints contributes to conflicting findings. Additionally, isolated in vitro systems lack systemic interactions, and sex- and dose-dependent effects can mask functional or structural defects. Addressing these gaps through longitudinal, low-dose, and sex-stratified studies is essential to clarify BPA’s impact on human skeletal muscle. To bridge the gap between systemic epidemiological associations and molecular animal data, future studies should incorporate direct human skeletal muscle assessments, such as proteomic and transcriptomic analysis of muscle biopsies from cohorts with high environmental BPA exposure. Concluding remarks Collectively, available evidence identifies skeletal muscle as a biologically relevant target of BPA exposure. Experimental studies demonstrate that BPA disrupts muscle insulin signaling, promotes inflammatory and immune-related transcriptional programs, and impairs glucose utilization. Developmental exposure further alters muscle fiber composition, calcium signaling, and structural integrity, suggesting that early-life BPA exposure may program long-term susceptibility to metabolic dysfunction, in part by promoting shifts toward glycolytic, insulin-insensitive muscle phenotypes. Despite these advances, critical gaps remain in understanding how environmentally relevant chronic BPA exposure affects skeletal muscle across the lifespan. Most studies rely on acute or high-dose animal models, limiting direct extrapolation to human exposure scenarios. Moreover, the interaction between BPA-induced oxidative stress, endocrine disruption, and muscle-specific signaling pathways remains insufficiently characterized. In addition, human studies assessing skeletal muscle-specific endpoints are limited, and most epidemiological evidence relies on systemic metabolic outcomes rather than direct measures of muscle function or insulin sensitivity. The documented sexual dimorphism in BPA’s effects further underscores the critical necessity for sex-stratified analysis in future muscle-specific studies. In summary, BPA-induced alterations in skeletal muscle development and metabolism may represent an underrecognized contributor to systemic metabolic disease risk. Future studies integrating longitudinal exposure paradigms, sex-specific analyses, and translational human data will be essential to define the long-term toxicological significance of BPA exposure and to inform regulatory risk assessment. Such approaches should also prioritize low-dose, environmentally relevant exposures and standardized methodological frameworks to improve comparability across studies. Acknowledgements N/A. Author contributions All authors reviewed the manuscript. Funding This work was supported by a 2023 and 2024 Midwestern University Core Outsourcing Awards (to Isabel Martinez-Pena y Valenzuela). Data availability No datasets were generated or analysed during the current study. Declarations Ethical approval Not applicable. Consent to participate Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Citations Data Availability Statement No datasets were generated or analysed during the current study.